Compare NVEC & CERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NVEC | CERS |
|---|---|---|
| Founded | 1989 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | EDP Services |
| Sector | Technology | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 328.9M | 276.0M |
| IPO Year | 1996 | 1997 |
| Metric | NVEC | CERS |
|---|---|---|
| Price | $66.93 | $2.74 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 60.4K | ★ 1.7M |
| Earning Date | 01-21-2026 | 02-19-2026 |
| Dividend Yield | ★ 6.13% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.85 | N/A |
| Revenue | $24,784,396.00 | ★ $199,191,000.00 |
| Revenue This Year | N/A | $25.31 |
| Revenue Next Year | N/A | $9.50 |
| P/E Ratio | $22.82 | ★ N/A |
| Revenue Growth | N/A | ★ 13.03 |
| 52 Week Low | $51.50 | $1.12 |
| 52 Week High | $84.64 | $2.96 |
| Indicator | NVEC | CERS |
|---|---|---|
| Relative Strength Index (RSI) | 57.61 | 78.87 |
| Support Level | $62.67 | $1.96 |
| Resistance Level | $65.45 | $2.96 |
| Average True Range (ATR) | 2.15 | 0.14 |
| MACD | 0.42 | 0.06 |
| Stochastic Oscillator | 87.82 | 78.90 |
NVE Corp develops and sells devices that use spintronics, a nanotechnology that relies on electron spin. It manufactures high-performance spintronic products including sensors and couplers that are used to acquire and transmit data. The company's products include Digital sensors, Medical sensors, Rotation Sensors, GT Sensors, Angle Sensors, Analog sensors, MSOP Isolators, Passive-In Transceivers, and others. The company manufactures high-performance spintronic products including sensors and couplers. The company's designs are based on giant magnetoresistance GMR and tunneling magnetoresistance TMR combined with integrated circuitry.
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.